Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up
Purpose To evaluate the safety and efficacy of intravitreal bevacizumab in Chinese patients with choroidal neovascularization (CNV) secondary to pathologic myopia. Methods Eight eyes of consecutive patients with myopic CNV without earlier treatment were treated with intravitreal injection of bevaciz...
Gespeichert in:
Veröffentlicht in: | Eye (London) 2009-11, Vol.23 (11), p.2042-2045 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 2045 |
---|---|
container_issue | 11 |
container_start_page | 2042 |
container_title | Eye (London) |
container_volume | 23 |
creator | Wu, P-C Chen, Y-J |
description | Purpose
To evaluate the safety and efficacy of intravitreal bevacizumab in Chinese patients with choroidal neovascularization (CNV) secondary to pathologic myopia.
Methods
Eight eyes of consecutive patients with myopic CNV without earlier treatment were treated with intravitreal injection of bevacizumab (2.5 mg). All patients underwent a clinical examination, which included visual acuity measurements, fundus photography, fluorescein angiography, and optical coherence tomography.
Results
Eight eyes of eight patients with ages ranging from 26 to 62 years (mean 41.5 years) were enroled. The follow-up period ranged from 13 to 17 months (mean, 14.9 months). At the 12-month follow-up, vision had improved in all eyes by three or more lines. However, a new-onset CNV adjacent to the earlier lesion and visual loss of one line at the 16th month were observed in one eye. The mean VA had significantly improved from the baseline value 20/82 to 20/25 (
P
=0.017). The final mean central retinal thickness was 214.1±36.3
μ
m, with a mean decrease of 59.8
μ
m from the pre-treatment value (
P
=0.017). The mean number of injections was 1.4 (ranging from 1 to 2) within 12 months. No other ocular or systemic side effects were noted.
Conclusions
In this small series of patients with 1-year follow-up, intravitreal injection of 2.5 mg bevacizumab seems to be effective and safe in patients with myopic CNV. |
doi_str_mv | 10.1038/eye.2008.404 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_734134044</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>734134044</sourcerecordid><originalsourceid>FETCH-LOGICAL-c520t-2796cf7f6c7dd5a02ac1e57e186d41e49fbad540b40c7f2467dbdbda1336076f3</originalsourceid><addsrcrecordid>eNp90c1rFDEUAPAgFru23jzLIKiXzjbJ5GPGWymtLRS8WOgtvMkkmmVmsiYzK9u_vm_ZxYJIySGH_PI-CXnP6JLRqj53W7fklNZLQcUrsmBCq1IKKV6TBW0kLTnnD8fkbc4rSvFR0zfkmDVMMiX5gpjbcUqwCVNy0BdhXDk7hTgW0Ret24ANj_MAbeFjKoZtXAdb2F8xxdChHl3cQLZzDyk8wu7b14KVWwcJfd_HP-W8PiVHHvrs3h3uE3J_ffXj8qa8-_7t9vLirrSS06nkulHWa6-s7joJlINlTmrHatUJ5kTjW-ikoK2gVnsulO5aPMCqSlGtfHVCvuzjrlP8Pbs8mSFk6_oesMo5G10JVuGEBMrPL0rOeC0rxRF-_Aeu4pxG7AJNXTVCS4bobI9sijkn5806hQHS1jBqdvsxuB-z24_B7Mg_HGLO7eC6Z3xYCIJPB4CThd4nGG3Ifx3nTGLLCl25dxmfxp8uPRf338RPfjuoAQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>218394751</pqid></control><display><type>article</type><title>Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Wu, P-C ; Chen, Y-J</creator><creatorcontrib>Wu, P-C ; Chen, Y-J</creatorcontrib><description>Purpose
To evaluate the safety and efficacy of intravitreal bevacizumab in Chinese patients with choroidal neovascularization (CNV) secondary to pathologic myopia.
Methods
Eight eyes of consecutive patients with myopic CNV without earlier treatment were treated with intravitreal injection of bevacizumab (2.5 mg). All patients underwent a clinical examination, which included visual acuity measurements, fundus photography, fluorescein angiography, and optical coherence tomography.
Results
Eight eyes of eight patients with ages ranging from 26 to 62 years (mean 41.5 years) were enroled. The follow-up period ranged from 13 to 17 months (mean, 14.9 months). At the 12-month follow-up, vision had improved in all eyes by three or more lines. However, a new-onset CNV adjacent to the earlier lesion and visual loss of one line at the 16th month were observed in one eye. The mean VA had significantly improved from the baseline value 20/82 to 20/25 (
P
=0.017). The final mean central retinal thickness was 214.1±36.3
μ
m, with a mean decrease of 59.8
μ
m from the pre-treatment value (
P
=0.017). The mean number of injections was 1.4 (ranging from 1 to 2) within 12 months. No other ocular or systemic side effects were noted.
Conclusions
In this small series of patients with 1-year follow-up, intravitreal injection of 2.5 mg bevacizumab seems to be effective and safe in patients with myopic CNV.</description><identifier>ISSN: 0950-222X</identifier><identifier>EISSN: 1476-5454</identifier><identifier>DOI: 10.1038/eye.2008.404</identifier><identifier>PMID: 19151652</identifier><identifier>CODEN: EYEEEC</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Adult ; Angiogenesis Inhibitors - therapeutic use ; Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Humanized ; Asian Continental Ancestry Group ; Bevacizumab ; Biological and medical sciences ; China ; Choroidal Neovascularization - drug therapy ; Choroidal Neovascularization - physiopathology ; clinical-study ; Female ; Follow-Up Studies ; Fundus Oculi ; Humans ; Intravitreal Injections ; Laboratory Medicine ; Male ; Medical sciences ; Medicine ; Medicine & Public Health ; Middle Aged ; Miscellaneous ; Myopia - complications ; Myopia - physiopathology ; Ophthalmology ; Pharmaceutical Sciences/Technology ; Surgery ; Surgical Oncology ; Tomography, Optical Coherence ; Vision disorders ; Visual Acuity</subject><ispartof>Eye (London), 2009-11, Vol.23 (11), p.2042-2045</ispartof><rights>Royal College of Ophthalmologists 2009</rights><rights>2015 INIST-CNRS</rights><rights>Copyright Nature Publishing Group Nov 2009</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c520t-2796cf7f6c7dd5a02ac1e57e186d41e49fbad540b40c7f2467dbdbda1336076f3</citedby><cites>FETCH-LOGICAL-c520t-2796cf7f6c7dd5a02ac1e57e186d41e49fbad540b40c7f2467dbdbda1336076f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/eye.2008.404$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/eye.2008.404$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22153366$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19151652$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wu, P-C</creatorcontrib><creatorcontrib>Chen, Y-J</creatorcontrib><title>Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up</title><title>Eye (London)</title><addtitle>Eye</addtitle><addtitle>Eye (Lond)</addtitle><description>Purpose
To evaluate the safety and efficacy of intravitreal bevacizumab in Chinese patients with choroidal neovascularization (CNV) secondary to pathologic myopia.
Methods
Eight eyes of consecutive patients with myopic CNV without earlier treatment were treated with intravitreal injection of bevacizumab (2.5 mg). All patients underwent a clinical examination, which included visual acuity measurements, fundus photography, fluorescein angiography, and optical coherence tomography.
Results
Eight eyes of eight patients with ages ranging from 26 to 62 years (mean 41.5 years) were enroled. The follow-up period ranged from 13 to 17 months (mean, 14.9 months). At the 12-month follow-up, vision had improved in all eyes by three or more lines. However, a new-onset CNV adjacent to the earlier lesion and visual loss of one line at the 16th month were observed in one eye. The mean VA had significantly improved from the baseline value 20/82 to 20/25 (
P
=0.017). The final mean central retinal thickness was 214.1±36.3
μ
m, with a mean decrease of 59.8
μ
m from the pre-treatment value (
P
=0.017). The mean number of injections was 1.4 (ranging from 1 to 2) within 12 months. No other ocular or systemic side effects were noted.
Conclusions
In this small series of patients with 1-year follow-up, intravitreal injection of 2.5 mg bevacizumab seems to be effective and safe in patients with myopic CNV.</description><subject>Adult</subject><subject>Angiogenesis Inhibitors - therapeutic use</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Asian Continental Ancestry Group</subject><subject>Bevacizumab</subject><subject>Biological and medical sciences</subject><subject>China</subject><subject>Choroidal Neovascularization - drug therapy</subject><subject>Choroidal Neovascularization - physiopathology</subject><subject>clinical-study</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Fundus Oculi</subject><subject>Humans</subject><subject>Intravitreal Injections</subject><subject>Laboratory Medicine</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Miscellaneous</subject><subject>Myopia - complications</subject><subject>Myopia - physiopathology</subject><subject>Ophthalmology</subject><subject>Pharmaceutical Sciences/Technology</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><subject>Tomography, Optical Coherence</subject><subject>Vision disorders</subject><subject>Visual Acuity</subject><issn>0950-222X</issn><issn>1476-5454</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp90c1rFDEUAPAgFru23jzLIKiXzjbJ5GPGWymtLRS8WOgtvMkkmmVmsiYzK9u_vm_ZxYJIySGH_PI-CXnP6JLRqj53W7fklNZLQcUrsmBCq1IKKV6TBW0kLTnnD8fkbc4rSvFR0zfkmDVMMiX5gpjbcUqwCVNy0BdhXDk7hTgW0Ret24ANj_MAbeFjKoZtXAdb2F8xxdChHl3cQLZzDyk8wu7b14KVWwcJfd_HP-W8PiVHHvrs3h3uE3J_ffXj8qa8-_7t9vLirrSS06nkulHWa6-s7joJlINlTmrHatUJ5kTjW-ikoK2gVnsulO5aPMCqSlGtfHVCvuzjrlP8Pbs8mSFk6_oesMo5G10JVuGEBMrPL0rOeC0rxRF-_Aeu4pxG7AJNXTVCS4bobI9sijkn5806hQHS1jBqdvsxuB-z24_B7Mg_HGLO7eC6Z3xYCIJPB4CThd4nGG3Ifx3nTGLLCl25dxmfxp8uPRf338RPfjuoAQ</recordid><startdate>20091101</startdate><enddate>20091101</enddate><creator>Wu, P-C</creator><creator>Chen, Y-J</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7T2</scope><scope>7U2</scope><scope>C1K</scope><scope>7X8</scope></search><sort><creationdate>20091101</creationdate><title>Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up</title><author>Wu, P-C ; Chen, Y-J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c520t-2796cf7f6c7dd5a02ac1e57e186d41e49fbad540b40c7f2467dbdbda1336076f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adult</topic><topic>Angiogenesis Inhibitors - therapeutic use</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Asian Continental Ancestry Group</topic><topic>Bevacizumab</topic><topic>Biological and medical sciences</topic><topic>China</topic><topic>Choroidal Neovascularization - drug therapy</topic><topic>Choroidal Neovascularization - physiopathology</topic><topic>clinical-study</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Fundus Oculi</topic><topic>Humans</topic><topic>Intravitreal Injections</topic><topic>Laboratory Medicine</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Miscellaneous</topic><topic>Myopia - complications</topic><topic>Myopia - physiopathology</topic><topic>Ophthalmology</topic><topic>Pharmaceutical Sciences/Technology</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><topic>Tomography, Optical Coherence</topic><topic>Vision disorders</topic><topic>Visual Acuity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wu, P-C</creatorcontrib><creatorcontrib>Chen, Y-J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied & Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Safety Science and Risk</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><jtitle>Eye (London)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wu, P-C</au><au>Chen, Y-J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up</atitle><jtitle>Eye (London)</jtitle><stitle>Eye</stitle><addtitle>Eye (Lond)</addtitle><date>2009-11-01</date><risdate>2009</risdate><volume>23</volume><issue>11</issue><spage>2042</spage><epage>2045</epage><pages>2042-2045</pages><issn>0950-222X</issn><eissn>1476-5454</eissn><coden>EYEEEC</coden><abstract>Purpose
To evaluate the safety and efficacy of intravitreal bevacizumab in Chinese patients with choroidal neovascularization (CNV) secondary to pathologic myopia.
Methods
Eight eyes of consecutive patients with myopic CNV without earlier treatment were treated with intravitreal injection of bevacizumab (2.5 mg). All patients underwent a clinical examination, which included visual acuity measurements, fundus photography, fluorescein angiography, and optical coherence tomography.
Results
Eight eyes of eight patients with ages ranging from 26 to 62 years (mean 41.5 years) were enroled. The follow-up period ranged from 13 to 17 months (mean, 14.9 months). At the 12-month follow-up, vision had improved in all eyes by three or more lines. However, a new-onset CNV adjacent to the earlier lesion and visual loss of one line at the 16th month were observed in one eye. The mean VA had significantly improved from the baseline value 20/82 to 20/25 (
P
=0.017). The final mean central retinal thickness was 214.1±36.3
μ
m, with a mean decrease of 59.8
μ
m from the pre-treatment value (
P
=0.017). The mean number of injections was 1.4 (ranging from 1 to 2) within 12 months. No other ocular or systemic side effects were noted.
Conclusions
In this small series of patients with 1-year follow-up, intravitreal injection of 2.5 mg bevacizumab seems to be effective and safe in patients with myopic CNV.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>19151652</pmid><doi>10.1038/eye.2008.404</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0950-222X |
ispartof | Eye (London), 2009-11, Vol.23 (11), p.2042-2045 |
issn | 0950-222X 1476-5454 |
language | eng |
recordid | cdi_proquest_miscellaneous_734134044 |
source | MEDLINE; Springer Nature - Complete Springer Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
subjects | Adult Angiogenesis Inhibitors - therapeutic use Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Asian Continental Ancestry Group Bevacizumab Biological and medical sciences China Choroidal Neovascularization - drug therapy Choroidal Neovascularization - physiopathology clinical-study Female Follow-Up Studies Fundus Oculi Humans Intravitreal Injections Laboratory Medicine Male Medical sciences Medicine Medicine & Public Health Middle Aged Miscellaneous Myopia - complications Myopia - physiopathology Ophthalmology Pharmaceutical Sciences/Technology Surgery Surgical Oncology Tomography, Optical Coherence Vision disorders Visual Acuity |
title | Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T22%3A25%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intravitreal%20injection%20of%20bevacizumab%20for%20myopic%20choroidal%20neovascularization:%201-year%20follow-up&rft.jtitle=Eye%20(London)&rft.au=Wu,%20P-C&rft.date=2009-11-01&rft.volume=23&rft.issue=11&rft.spage=2042&rft.epage=2045&rft.pages=2042-2045&rft.issn=0950-222X&rft.eissn=1476-5454&rft.coden=EYEEEC&rft_id=info:doi/10.1038/eye.2008.404&rft_dat=%3Cproquest_cross%3E734134044%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=218394751&rft_id=info:pmid/19151652&rfr_iscdi=true |